Pediatric PRVs, Biosecure & Novo’s obesity miss: a BioCentury podcast

Misunderstandings on priority review vouchers in Congress. A door closes for Biosecure. Setback for Novo Nordisk

Rep. Frank Pallone’s misunderstanding of how the pediatric priority review voucher program works has been one factor undermining support for an incentive that brings new drugs to kids, argues Washington Editor Steve Usdin on the latest BioCentury This Week podcast. Usdin explains how the voucher process works and why it’s valuable to the country’s youngest patients, as well as to small biotechs and larger biopharma alike.

Usdin also discusses the latest twists and turns for the Biosecure Act as it moves through Congress. The bill, which seeks to rein in the influence of Chinese CDMOs and genomics companies in the U.S., was dealt a setback in the Senate last week when it was left out of a piece of must-pass legislation.

Finally, BioCentury’s Stephen Hansen joins the podcast to assess obesity data from Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) that destroyed more than $30 billion in value for the Danish pharma.

This episode of BioCentury This Week was sponsored by Parexel Biotech. For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com. To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.